MA35210B1 - Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer - Google Patents

Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer

Info

Publication number
MA35210B1
MA35210B1 MA36616A MA36616A MA35210B1 MA 35210 B1 MA35210 B1 MA 35210B1 MA 36616 A MA36616 A MA 36616A MA 36616 A MA36616 A MA 36616A MA 35210 B1 MA35210 B1 MA 35210B1
Authority
MA
Morocco
Prior art keywords
inhibitor
cdk4
cancer
treatment
combination therapy
Prior art date
Application number
MA36616A
Other languages
English (en)
Inventor
Sunkyu Kim
Shivang Doshi
Kristy Haas
Steven Kovats
Alan Xizhong Huang
Yan Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35210(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA35210B1 publication Critical patent/MA35210B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une combinaison d'un inhibiteur de cdk4/6 et d'un inhibiteur de p3kinase pour le traitement du cancer.
MA36616A 2011-07-01 2013-12-26 Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer MA35210B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503642P 2011-07-01 2011-07-01
PCT/US2012/045199 WO2013006532A1 (fr) 2011-07-01 2012-07-02 Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer

Publications (1)

Publication Number Publication Date
MA35210B1 true MA35210B1 (fr) 2014-06-02

Family

ID=46513871

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36616A MA35210B1 (fr) 2011-07-01 2013-12-26 Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer

Country Status (23)

Country Link
US (2) US9271988B2 (fr)
EP (1) EP2726074B1 (fr)
JP (2) JP5832647B2 (fr)
KR (1) KR20140040770A (fr)
CN (1) CN103635189B (fr)
AU (3) AU2012279117A1 (fr)
BR (1) BR112013033940A2 (fr)
CA (1) CA2840754A1 (fr)
CL (1) CL2013003805A1 (fr)
CO (1) CO6842016A2 (fr)
EA (1) EA030465B1 (fr)
ES (1) ES2676180T3 (fr)
GT (1) GT201300320A (fr)
IL (1) IL229876B (fr)
MA (1) MA35210B1 (fr)
MX (1) MX359406B (fr)
MY (1) MY161237A (fr)
PE (1) PE20141381A1 (fr)
PH (1) PH12013502697A1 (fr)
TN (1) TN2013000508A1 (fr)
UA (1) UA114178C2 (fr)
WO (1) WO2013006532A1 (fr)
ZA (1) ZA201309241B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
PE20141381A1 (es) * 2011-07-01 2014-10-21 Novartis Ag Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
CN104244949A (zh) * 2012-03-30 2014-12-24 诺华股份有限公司 用于治疗神经母细胞瘤、尤文氏肉瘤或横纹肌肉瘤的化合物
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA3163776A1 (fr) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Papillomavirus humain en tant que predicteur du pronostic du cancer
SMT201800561T1 (it) 2012-11-01 2018-11-09 Infinity Pharmaceuticals Inc Trattamento di cancri usando modulatori di isoforme di pi3 chinasi
EP2742940B1 (fr) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Sel de fumarate de (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane destinés à être administrés une fois par jour, deux fois par jour ou trois fois par jour
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
CN105407889B (zh) 2013-03-15 2018-06-01 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
WO2015022609A1 (fr) 2013-08-14 2015-02-19 Novartis Ag Polythérapie pour le traitement du cancer
WO2015160986A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015161283A1 (fr) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Lactames tricycliques à utiliser dans des traitements de la prolifération de cellules anormales rb-positives, épargnant les cellules souches et les cellules progénitrices hématopoïétiques (hspc)
WO2016040848A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Traitement de tumeurs rb-négatives en utilisant des inhibiteurs de la topoisomérase en association avec des inhibiteurs des kinases cycline-dépendantes 4/6
WO2016040858A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinaisons et régimes posologiques pour traiter des tumeurs rb-positives
PL3317284T3 (pl) 2015-07-02 2020-04-30 F. Hoffmann-La Roche Ag Związki oksazolidynonu benzoksazepiny i sposoby stosowania
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
WO2017037575A1 (fr) * 2015-08-28 2017-03-09 Novartis Ag Combinaison pharmaceutique comprenant l'inhibiteur de pi3k alpelisib et l'inhibiteur de cdk4/6 ribociclib et son utilisation dans le traitement/la prévention du cancer
WO2017172734A1 (fr) 2016-03-29 2017-10-05 Mayo Foundation For Medical Education And Research Traitement de métastases cancéreuses
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
WO2018017410A1 (fr) 2016-07-22 2018-01-25 Eli Lilly And Company Polythérapie à base d'abemaciclib et d'un inhibiteur double de kinase pi3 /mtor, destinée à être utilisée dans le traitement du cancer du sein
WO2018081211A1 (fr) * 2016-10-26 2018-05-03 Li George Y 7-cyclopentyl-n,n-diméthyl-2-((5- (pipérazin-1-yl)pyridin-2-yl)amino)-7h- pyrrolo[2,3-d]pyrimidine-6-carboxamide deutéré
IL303038B2 (en) 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
RU2020123665A (ru) 2018-01-08 2022-02-10 Г1 Терапьютикс, Инк. Преимущественные режимы дозирования g1т38
DK3762004T3 (da) * 2018-03-05 2023-11-27 Klinikum Rechts Der Isar Der Technischen Univ Muenchen Behandling af tumorer ved hjælp af en kombination af en oncolytisk adenovirus og en CDK4/6 inhibitor
CN111184863B (zh) * 2018-11-15 2023-06-16 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US20240307393A1 (en) * 2021-07-06 2024-09-19 National Cancer Center Pharmaceutical composition for cancer prevention or treatment, comprising cdk4/6 inhibitor and tricyclic antidepressant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AU2003295776B2 (en) 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
KR101277823B1 (ko) 2008-02-06 2013-07-15 노파르티스 아게 피롤로［２,３­ｄ］피리미딘 및 티로신 키나제 억제제로서 그의 용도
NZ591176A (en) * 2008-08-22 2012-11-30 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR20130119928A (ko) 2010-10-01 2013-11-01 노파르티스 아게 피리미딘 유도체의 제조 방법
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
PE20141381A1 (es) * 2011-07-01 2014-10-21 Novartis Ag Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
CA2891938A1 (fr) * 2012-11-28 2014-06-05 Novartis Ag Polytherapie

Also Published As

Publication number Publication date
CN103635189A (zh) 2014-03-12
EP2726074A1 (fr) 2014-05-07
PH12013502697A1 (en) 2014-02-10
EA030465B1 (ru) 2018-08-31
ES2676180T3 (es) 2018-07-17
AU2012279117A1 (en) 2014-01-09
CO6842016A2 (es) 2014-01-20
AU2017232162A1 (en) 2017-10-12
US20140107114A1 (en) 2014-04-17
GT201300320A (es) 2016-03-01
MX2013015370A (es) 2014-02-11
MY161237A (en) 2017-04-14
US20160136171A1 (en) 2016-05-19
US9271988B2 (en) 2016-03-01
CN103635189B (zh) 2016-05-04
KR20140040770A (ko) 2014-04-03
AU2017232162B2 (en) 2019-03-07
US10010552B2 (en) 2018-07-03
PE20141381A1 (es) 2014-10-21
CA2840754A1 (fr) 2013-01-10
JP5832647B2 (ja) 2015-12-16
WO2013006532A1 (fr) 2013-01-10
MX359406B (es) 2018-09-27
TN2013000508A1 (en) 2015-03-30
EA201490194A1 (ru) 2014-04-30
BR112013033940A2 (pt) 2017-02-14
CL2013003805A1 (es) 2014-08-08
EP2726074B1 (fr) 2018-04-04
ZA201309241B (en) 2014-08-27
JP2014518279A (ja) 2014-07-28
AU2016202213A1 (en) 2016-05-05
UA114178C2 (uk) 2017-05-10
IL229876B (en) 2018-10-31
JP2016027043A (ja) 2016-02-18

Similar Documents

Publication Publication Date Title
MA35210B1 (fr) Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer
EP2911669A4 (fr) Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
FR22C1002I2 (fr) Inhibiteurs ibat pour le traitement de maladies du foie
EP2154971A4 (fr) Combinaison pharmaceutique synergique pour le traitement du cancer
EP2710137A4 (fr) Combinaison de thérapies immunomodulatrices locales et systémiques pour l'amélioration du traitement du cancer
EP2793882A4 (fr) Administration de promédicaments activés par l'hypoxie en combinaison à des inhibiteurs de chk1 pour le traitement du cancer
EP2593139A4 (fr) Administration de promédicaments activés par hypoxie et d'agents anti-angiogéniques pour le traitement du cancer
EP2763988A4 (fr) Composés pyrrolopyrimidines pour le traitement du cancer
EP2740793A4 (fr) Composition de médicament pour traitement et/ou prévention du cancer
EP2740795A4 (fr) Composition de médicament pour traitement et/ou prévention du cancer
EP2740798A4 (fr) Composition de médicament pour traitement et/ou prévention du cancer
EP2788378A4 (fr) Thérapie d'association pour le traitement du cancer
EP2818483A4 (fr) Composition médicinale pour le traitement et/ou la prévention du cancer
EP2598168A4 (fr) Polythérapie pour le traitement du cancer comprenant un inhibiteur d'igf-1r et un inhibiteur d'akt
MX2014000578A (es) Tratamiento con anticuerpos anti-pcsk9.
EP2756521A4 (fr) Lymphocytes t à arn modifié pour le traitement du cancer
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
EP2623494A4 (fr) Agent pour le traitement de maladies oculaires
EP2776042A4 (fr) Polythérapie médicamenteuse pour le traitement de tumeurs solides
EP2837381A4 (fr) Utilisation d'agents modificateurs de l'environnement péritumoral pour le traitement du cancer
EP2685990A4 (fr) Combinaison d'un oligonucléotide anti-clusterine et de l'inhibiteur hsp90 pour le traitement du cancer de la prostate
EP2758134A4 (fr) Buprénorphine pour le traitement d'une tendance suicidaire aiguë
EP2254411A4 (fr) Inhibiteurs du complément en tant qu'agents thérapeutiques pour le traitement du cancer
EP2608671A4 (fr) Composés utilisés dans le traitement du cancer